GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.88
+25.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.0K | — | — | — | — |
| Gross Profit | (1.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 2.8M | 6.8M | 3.8M | 3.2M | 242.0K |
| SG&A Expense | 5.6M | 5.2M | 4.5M | 8.2M | 2.0M |
| General & Admin Expense | 5.6M | 5.2M | 4.5M | 8.2M | 2.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 8.3M | 12.0M | 8.2M | 11.4M | 2.2M |
| Cost and Expenses | 8.3M | 12.0M | 8.2M | 11.4M | 2.2M |
| Operating Income (EBIT) | (8.3M) | (12.0M) | (8.2M) | (11.4M) | (2.2M) |
| Non-Operating | |||||
| Interest Income | 20.0K | 21.0K | 25.0K | — | — |
| Interest Expense | — | — | — | 2.1M | 653.0K |
| Net Interest Income | 20.0K | 21.0K | 25.0K | (2.1M) | (653.0K) |
| Other Non-Op Income/Expense | 20.0K | 21.0K | 28.0K | (1.6M) | (978.0K) |
| Non-Operating Income (excl Interest) | — | — | — | (432.0K) | 325.0K |
| EBT (Pre-Tax Income) | (8.3M) | (12.0M) | (8.2M) | (13.0M) | (3.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (8.3M) | (12.0M) | (8.2M) | (13.0M) | (3.2M) |
| Earnings from Cont. Ops | (8.3M) | (12.0M) | (8.2M) | (13.0M) | (3.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.3M) | (12.0M) | (10.1M) | (13.0M) | (3.2M) |
| Per Share | |||||
| Basic EPS | ($9.47) | ($121.80) | $0.33 | ($140,450.24) | ($47,135.48) |
| Diluted EPS | ($9.47) | ($121.80) | $0.33 | ($140,450.24) | ($47,135.48) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.8M | 98162 | 4.9M | 1578 | 1160 |
| Diluted Shares Outstanding | 1.8M | 98162 | 4.9M | 1578 | 1160 |
| Profitability Metrics | |||||
| EBITDA | (8.3M) | (12.0M) | (8.2M) | (11.0M) | (2.6M) |
| D&A | 3.0K | 4.0K | 4.0K | 4.0K | 3.0K |
| EBIT | (8.3M) | (12.0M) | (8.2M) | (11.0M) | (2.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026